Autres langues Unity Biotechnology, Inc.

Actions

UBX

US91381U2006

Temps Différé Nasdaq Autres places de cotation 20:45:08 16/05/2024			Varia. 5j.	Varia. 1 janv.
1,485 ^USD	-2,94 %		-7,19 %	-23,06 %

23/04	Unity Biotechnology, Inc. Annonce l'extension de l'étude clinique de phase 2b ASPIRE évaluant UBX1325 dans l'OMD	CI
16/04	UNITY BIOTECHNOLOGY, INC. : HC Wainwright toujours à l'achat	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates	14/05
UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting	25/04
Unity Biotechnology Adds More Patients, Extends Length of Trial of Prospective Macular Edema Treatment	23/04
UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME	23/04
Unity Biotechnology, Inc. Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME	23/04
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates	15/04
Unity Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15/04
Unity Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/04
North American Morning Briefing : Stocks Seen -2-	02/04
North American Morning Briefing : Markets Steady -2-	26/03
New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss	06/02
Unity Biotechnology, Inc. Announces New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-Lasting, Disease-Modifying Intervention in Vision Loss	06/02
UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME	12/12
Unity Biotechnology, Inc. Doses First Patients in Phase 2 Aspire Study of Ubx1325 in DME	12/12
North American Morning Briefing : Stocks Futures -2-	20/11
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates	13/11
Unity Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Sector Update: Health Care Stocks Rising Late Afternoon	10/11
Sector Update: Health Care	10/11
Unity Biotechnology Agrees to Exercise Warrants for $4.38 Million in Gross Proceeds; Shares Fall	10/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Unity Biotechnology, Inc.

Actions

UBX

US91381U2006

Autres langues

Filtres